A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC #704865) In Patients With Malignant Mesotheloma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- Time to disease progression
研究概览
简要总结
This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known if combination chemotherapy works better with or without bevacizumab in treating malignant mesothelioma.
详细描述
OBJECTIVES:
I. Compare the time to progression of patients with malignant mesothelioma treated with gemcitabine and cisplatin with or without bevacizumab.
II. Compare the objective response rate in patients treated with these regimens.
III. Compare the toxicity of these regimens when administered to these patients.
IV. Compare the median and overall survival of patients treated with these regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma that is not amenable to curative surgery
- •Epithelial, sarcomatoid, or mixed subtype
- •Evidence of gross unresectability, including, but not limited to, the following conditions:
- •Direct extension into the chest wall
- •Mediastinal or hilar lymphadenopathy
- •Pulmonary or cardiac function that is inadequate to tolerate resection
- •Sarcomatoid or mixed histology
- •Pleural mesothelioma must be stage II or greater using the International Mesothelioma Interest Group staging system
- •Measurable disease outside prior irradiation port
- •At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- •Pleural effusions and ascites are not considered measurable lesions
- •Site in pleura, lung, liver, or retroperitoneum that can be assessed by MRI for evaluation of blood flow
- •No obvious tumor involvement of major vessels by CT scan
- •No known brain metastases
- •Performance status - ECOG 0-1
- •More than 3 months
- •WBC at least 3,000/mm^3
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •No history of bleeding diathesis
- •Bilirubin normal
- •AST/ALT no greater than 2.5 times upper limit of normal
- •INR no greater than 1.5
- •Creatinine no greater than 1.5 mg/dL
- •Creatinine clearance at least 60 mL/min
- •If 1+ or greater proteinuria on dipstick, then must have less than 500 mg of protein/24-hour urine collection
- •No significant renal impairment
- •See Disease Characteristics
- •No history deep vein thrombosis
- •No myocardial ischemia or infarction within the past 6 months
- •No uncompensated coronary artery disease within the past 6 months
- •No uncontrolled hypertension
- •No symptomatic congestive heart failure
- •No unstable angina pectoris within the past 6 months
- •No cardiac arrhythmia
- •No transient ischemic attack within the past 6 months
- •No cerebrovascular accident within the past 6 months
- •No other arterial thromboembolic event within the past 6 months
- •No clinically significant peripheral artery disease
- •See Disease Characteristics
- •No history of pulmonary embolism
- •No prior allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other study agents
- •No other active malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- •No ongoing or active infection
- •No other concurrent uncontrolled illness that would preclude study participation
- •No psychiatric illness or social situations that would preclude compliance
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No growth factors for 24 hours before, during, or for 24 hours after cytotoxic chemotherapy
- 另有 10 项未显示
排除标准
- 未提供
研究组 & 干预措施
Arm I
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: gemcitabine hydrochloride (Drug)
Arm I
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: cisplatin (Drug)
Arm I
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: bevacizumab (Biological)
Arm I
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
Arm II
Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
干预措施: gemcitabine hydrochloride (Drug)
Arm II
Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
干预措施: cisplatin (Drug)
Arm II
Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
干预措施: placebo (Other)
Arm II
Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Time to disease progression
时间窗: Time from randomization until the first evidence of progression, up to 9 years
The two treatment groups will be compared using a stratified logrank test. Kaplan-Meier time-to-event curves will be constructed for each treatment group. Median time-to-progression in each group and corresponding 95% confidence intervals will be derived using the method described in Brookmeyer and Crowley.
次要结局
- Complete response rate(Up to 6 months)
- Objective response rate (complete and partial response)(Up to 6 months)
- Rate of disease stabilization(Up to 6 months)
- Overall survival(Up to 9 years)
- Incidence of adverse events graded according to NCI CTCAE version 3.0(Up to 9 years)